SecBot SecBot
DEFA14A ·Filed Oct 26, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed1d 15h ago SEC0001193125-26-431945
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the December 15 annual meeting for vote outcomes, particularly the board declassification proposal and the ESPP approval, which could signal governance changes. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Zymeworks Inc. filed a DEFA14A notice of internet availability of proxy materials for its 2026 annual meeting of stockholders to be held on December 15, 2026. The filing is a routine administrative notice that directs shareholders to online proxy materials and lists the six proposals to be voted on, including election of three Class II directors, advisory votes on executive compensation, approval of the 2026 Employee Stock Purchase Plan, board declassification, and ratification of auditors. No material financial information or contested matters are disclosed.

Key Financial Metrics

Vote
director election
Meeting
2026-12-15

Key Facts

  • Annual meeting scheduled for December 15, 2026 at 9:00 am PT, virtual format
  • Board recommends voting FOR all director nominees (Brian N. Cherry, Gregory A. Ciongoli, Oleg Nodelman) and FOR Proposals 2, 4, 5, 6
  • Board recommends 1 YEAR for Proposal 3 (advisory vote on frequency of say-on-pay)
  • Proposal 5 seeks approval to declassify the board of directors
  • Proposal 4 seeks approval of the 2026 Employee Stock Purchase Plan (2,000,000 shares per the DEF 14A)
  • Proposal 6 seeks ratification of KPMG LLP as auditors for fiscal year ending December 31, 2026
  • Record date and meeting details are standard; no activist or dissident solicitation materials included

Financial Impact

No financial impact; routine proxy notice with no material financial data

Risk Factors

  • No material risks identified; this is a routine administrative filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-431945
Document: 0001193125-26-431945-index-headers.html0001193125-26-431945
Document: 0001193125-26-431945-index.html0001193125-26-431945
Document: 0001193125-26-431945.txt0001193125-26-431945
19 reports for ZYME
Performance horizon
70% Hit rate @ T+1 7 of 10 directional calls Went positive at some point 9 of 10 best @ T+60▲ +16.72%Jun 14, 2026
Filters
Rows
Reports for ZYME, sortable and filterable
TypeNow
Oct 26, 2026
1d ago
DEFA14A
NEUTRAL ★ 2/10
$28.23awaiting T+1awaiting T+1$28.85 (+2.20%)
Oct 26, 2026
1d ago
DEF 14A
NEUTRAL ★ 3/10
$28.37awaiting T+1awaiting T+1$28.85 (+1.69%)
Oct 23, 2026
5d ago
8-K
BULLISH ★ 7/10
$28.22 $28.37▲ +0.53%▼ −0.18%$28.85 (+2.23%)
Oct 15, 2026
13d ago
Press Release
NEUTRAL ★ 1/10
$25.75 $25.03▼ −2.80%▼ −1.69%$28.85 (+12.04%)
Oct 9, 2026
18d ago
144
NEUTRAL ★ 2/10
$25.79 $25.33▼ −1.78%▼ −1.72%$28.85 (+11.87%)
Sep 28, 2026
4w ago
Press Release
BULLISH ★ 7/10
$27.12 $27.20▲ +0.29%▲ +0.48%$28.85 (+6.38%)
Sep 23, 2026
4w ago
Press Release
BULLISH ★ 6/10
$26.81 $26.52▼ −1.08%▼ −1.63%$28.85 (+7.61%)
Aug 25, 2026
9w ago
8-K
BULLISH ★ 8/10
$27.47 $29.31▲ +6.68%▲ +6.66%$28.85 (+5.02%)
Jul 16, 2026
14w ago
Press Release
NEUTRAL ★ 1/10
$24.19awaiting T+1awaiting T+1$28.85 (+19.26%)
Jun 29, 2026
17w ago
Press Release
BULLISH ★ 7/10
$24.10 $26.14▲ +8.46%▲ +7.69%$28.85 (+19.71%)
Showing 10 of 19

US Market Status

Market Closed · Opens in 1h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026